Phase 1 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have liver cancer (hepatocellular carcinoma, or HCC) that has spread to nearby tissues, other parts of the body, or cannot be removed with surgery
- Your liver is still functioning reasonably well (a measure called Child-Pugh A — confirm with trial site)
- Your liver cancer is classified as stage B or C according to a specific staging system called Barcelona Clinic Liver Cancer (confirm with trial site)
- You are generally able to carry out daily activities with little or no limitation (scored 0 or 1 on a standard activity scale)
- You have previously been treated with a type of cancer medication called an immune checkpoint inhibitor as your first treatment for HCC
- Your blood counts and organ function (such as kidneys and liver) are at acceptable levels (confirm with trial site)
Who may not be able to join:
- You have cancer that has spread to the brain or spinal cord and is causing symptoms, has not been treated, or is getting worse
- You have had another type of cancer in the last 5 years, unless it was a cancer with a very low risk of spreading or being life-threatening
- You have a history of conditions where your immune system attacks your own body, such as rheumatoid arthritis, lupus, multiple sclerosis, or inflammatory bowel disease, among others
- You have had significant problems with your kidneys, nerves, mental health, hormones, heart, lungs, or liver in the last 6 months that could affect your ability to safely participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of Participants With Adverse Events (AE); Number of Participants with Dose-Limiting Toxicities (DLT); Maximum Plasma Concentration (Cmax) of Livmoniplimab and Budigalimab; Area Under the Serum Concentration Versus Time Curve (AUC) of Livmoniplimab and Budigalimab
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.